Evotec stock gains as Frankfurt trading shows early rebound signs
Published on 09/21/2026 at 13:43 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Evotec stock (ISIN DE0005664809) is trading higher in Frankfurt, with the biotechnology group’s shares up about 3 percent to around EUR 3.00 on September 21, 2026, offering investors a first technical rebound after a sharp slide over the past year.
Evotec stock rebounds in Frankfurt trading
According to finanzen.ch on September 21, 2026, Evotec SE is among the strongest stocks in the SDAX at the start of trading, gaining 2.95 percent to EUR 3.00, as smaller caps in Frankfurt move broadly higher.
A separate intraday overview from finanzen.ch on September 21, 2026, highlights Evotec SE again, noting a 2.95 percent rise to EUR 3.00 as one of the strongest individual values in the TecDAX-linked universe, underlining that the rebound is not isolated but part of a broader positive start to the session.
Fundamentals under pressure despite 1H 2026 figures
The price recovery comes against a backdrop of deteriorating fundamentals that were last visible in Evotec’s half-year 2026 figures. As Ground News reports in an analysis published on September 21, 2026, Evotec’s revenue in the first half of 2026 fell nearly 20 percent compared with the prior-year period, signalling a meaningful slowdown in its drug discovery and development business.
According to the same analysis from Ground News, adjusted EBITDA turned sharply negative in 1H 2026, contrasting with a positive level a year earlier and underlining that profitability has deteriorated faster than top-line trends. For investors, this means that the current share price recovery is taking place while operating margins are still deeply under pressure.
The combination of lower revenue and negative adjusted EBITDA in the first half of 2026 helps explain why Evotec’s share price had roughly halved over the past twelve months before the latest move. A commentary cited by Finanznachrichten on September 21, 2026, notes that Evotec’s stock had been a “desaster” over the last year and mentions a recent intraday rise of about 5 percent, framing such spikes as potential start of a rebound rather than confirmed trend reversals.
Analyst view and Nasdaq-listed Evotec ADR
Evotec is also traded in the United States via an ADR on Nasdaq under the ticker EVO, giving international investors direct access. A same-day overview from MarketBeat on September 21, 2026, shows the ADR trading around USD 1.60 within a 52-week range of USD 1.57 to USD 4.27, implying that even after the latest moves the US-listed instrument remains near its yearly low.
According to the same MarketBeat analyst overview dated September 21, 2026, Evotec carries a consensus rating of Hold from four analysts, with one buy, two hold and one sell recommendation, and an average price target of USD 3.00, representing about 87.5 percent upside from the current ADR price of USD 1.60. The range of targets between USD 2.00 and USD 4.00 reflects a market split on the company’s prospects, in line with the fundamental concerns highlighted elsewhere.
For risk-aware investors, the key comparison is that the ADR’s current price of roughly USD 1.60 stands close to the 52-week low of USD 1.57 and far below the high of USD 4.27, suggesting that the market has already priced in much of the recent profit deterioration, but also that there is considerable volatility embedded in the stock.
Stock price level and market capitalization
On the primary exchange Xetra, Evotec’s reference price for the latest completed trading day can be taken as approximately EUR 3.00 as of September 21, 2026, with an intraday gain of 2.95 percent compared with the prior close, per the SDAX and TecDAX overviews from finanzen.ch. In market-value terms, the Nasdaq ADR data imply a market capitalization of about USD 569.31 million as of September 21, 2026, highlighting how far the company’s valuation has come down from earlier peaks but still underlining its role as a mid-cap player in European biotechnology.
From a chart perspective, the recent intraday commentaries point to technical levels just below the EUR 3.00 mark. An Italian trading note from Teleborsa on September 21, 2026 mentions support levels around EUR 2.954 and immediate resistance at EUR 3.014, with a short-term technical target near EUR 3.074, illustrating that the rebound is being watched through a precise set of price thresholds.
Given the steep long-term decline, even relatively small moves around these levels can be significant. A daily increase of around 3 percent to EUR 3.00 on September 21, 2026 compares with roughly a 50 percent slide over the prior twelve months, implying that several days of similar gains would be needed to materially change the medium-term picture.
Evotec stock closing context for investors
As of September 21, 2026, Evotec stock around EUR 3.00 on Xetra and the EVO ADR at about USD 1.60 on Nasdaq leave the shares trading close to their respective 52-week lows and far below earlier highs, even after the latest rebound. For investors, the key tension remains between a depressed valuation of roughly USD 569.31 million and the weak 1H 2026 fundamentals, including nearly 20 percent lower revenue and sharply negative adjusted EBITDA, which together mean that any sustained recovery in the share price will likely depend on clearer evidence of operating improvement in upcoming reporting dates.
Evotec stock key data
- Company: Evotec SE
- ISIN: DE0005664809
- WKN: 566480
- Ticker: EVT
- Trading venue: Xetra
- Price (as of September 21, 2026): 3.00 EUR
- Market capitalization: 569.31 million USD (as of September 21, 2026)
- Sector / Industry: Biotechnology / Pharmaceuticals
- Index membership: SDAX
